Brand Intelligence Graph
Company Overview
About Mirador Therapeutics
Mirador Therapeutics is a precision immunology company with a genetics-first platform (Mirador360) that uses human genetic data to identify the most biologically validated targets and patient subpopulations for inflammatory and fibrotic diseases. The company closed a $250 million Series B in January 2026, bringing total funding above $650 million, with an ambitious pipeline targeting Crohn's disease, ulcerative colitis, rheumatoid arthritis, and idiopathic pulmonary fibrosis (IPF). Ten or more clinical readouts are expected by end of 2027.
Business Model & Competitive Advantage
Mirador's genetics-first approach is both a scientific and commercial differentiator: human genetic studies identify which biological pathways actually cause disease in humans, rather than relying on animal models that frequently fail to translate. This validation reduces clinical failure risk — the primary driver of biopharma R&D cost — by entering the clinic with the strongest possible biological rationale for each target.
Competitive Landscape 2025–2026
The extraordinary capital accumulation ($650M+) for a company still in clinical development reflects investor conviction that Mirador has the platform and expertise to become a generational immunology company. Immunology is one of the highest-value therapeutic categories: existing approved drugs (Humira, Dupixent, Skyrizi) generate $15-30 billion in annual revenue, and validated next-generation approaches to these diseases command premium valuations.
Key Differentiators
Strong Challenger
Mirador Therapeutics is an established challenger with significant market presence and competitive offerings in BioTech.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Florence Healthcare
Florence Healthcare is the dominant software platform for clinical trial site enablement, providing digital tools that connect trial sites, sponsors, and contract research organizations (CROs) to stre
DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a
Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US oper
Compare Mirador Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Mirador Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Mirador Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Mirador Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →